Gates Foundation Backing Phase III Clinical Trial Of New TB Drug Regimen
News outlets report on the announcement of a Phase III clinical trial for a drug regimen that has the potential to fight drug-resistant tuberculosis.
The Guardian: New and better treatments for drug-resistant tuberculosis on the horizon
“A new trial of a novel drug combination that could dramatically shorten treatment for tuberculosis, including some of the drug-resistant strains, will start within the year — as long as enough money can be raised…” (Boseley, 4/23).
Reuters: Gates-backed TB drug to enter late-stage testing
“The first experimental drug that fights both conventional and drug-resistant forms of tuberculosis is advancing to late-stage clinical testing, researchers said on Wednesday, raising hope for a new way to stem the growing threat of drug-resistant TB…” (Steenhuysen, 4/23).
Wall Street Journal: Gates Foundation to Fund New Tuberculosis Drug Trial
“The Bill & Melinda Gates Foundation said Wednesday it would help fund a clinical trial of a promising drug regimen that, if effective, would offer a powerful new tool to fight drug-resistant tuberculosis…” (McKay, 4/23).
TB Alliance: New Tuberculosis Drug Regimen Will Move to Landmark Phase III Clinical Trial
“Based on positive results from earlier clinical studies, TB Alliance is advancing the first-ever drug regimen designed to treat both drug-sensitive and some forms of multidrug-resistant tuberculosis (TB) to a global Phase III clinical trial…” (4/23).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.